Enzo Life Sciences expands its portfolio of drug discovery screening platforms by introducing the Leading Light Wnt reporter assay.

Alterations in Wnt expression, surface receptors, signaling partners, and the battery of Wnt-regulated genes (collectively the canonical Wnt pathway) are known to manifest in a variety of clinically relevant disease states, including cancer, osteoporosis, cardiovascular disease, diabetes, and neurodegeneration. Development of Wnt pathway altering drugs requires the ability to rapidly screen the effect of compounds and biological therapeutics on the expression of Wnt-regulated genes. The Leading Light Wnt Reporter Assay was developed to meet the market need for a high sensitivity system that accelerates screening analysis of Wnt pathway modulators. This product is a luciferase-based assay for the analysis of canonical Wnt signaling.  The Leading Light Wnt Reporter Assay guarantees confidence in the assay results by providing a system that is capable of detecting low concentration of effectors across a dynamic range of signal intensity.

The assay uses a 3T3 mouse fibroblast cell line modified with a luciferase reporter gene under the control of Wnt-responsive promoters (TCF/LEF). It provides a true endpoint detection system for screening compounds without the need for overexpression or alteration of pathway signaling molecules. With a chemiluminescent readout amenable to both 96-well and 384-well plate formats, the kit allows for high-throughput analysis of Wnt pathway activators and inhibitors. The Leading Light Wnt Reporter Assay Starter Kit is supplied with an easy-to-follow protocol, a validated cell line and all necessary media, reagents and controls. 

Enzo Life Sciences